Cardiol Therapeutics Inc Class A (CRDL) Stock Analysis

Cardiol Therapeutics Inc Class A (CRDL) is a publicly traded company in the HEALTHCARE sector. It trades at $1.15, carries a market capitalization of $140.63M. This page summarizes the public market data, fundamentals, and frequently asked questions for CRDL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cardiol Therapeutics Inc Class A currently has a Bullish sentiment score of 0.21.

About Cardiol Therapeutics Inc Class A

Cardiol Therapeutics Inc. (CRDL) is a clinical-stage biotechnology company headquartered in Oakville, Canada, focusing on the development of innovative anti-inflammatory therapies for cardiovascular diseases (CVD). With a strong pipeline supported by advanced research and development efforts, the company is committed to addressing pressing unmet medical needs in CVD treatment. By harnessing leading-edge science and expertise in inflammation, Cardiol Therapeutics aims to deliver novel therapeu...

GNG Research Analysis

GNG Research scores Cardiol Therapeutics Inc Class A (CRDL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CRDL.

Frequently Asked Questions

Does CRDL pay dividends?

Cardiol Therapeutics Inc Class A (CRDL) does not currently pay a regular dividend.

What is CRDL's market cap?

Cardiol Therapeutics Inc Class A (CRDL) has a market capitalization of $140.63M with a current stock price of $1.15.